- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 25/16 - Anti-Parkinson drugs
Patent holdings for IPC class A61P 25/16
Total number of patents in this class: 5450
10-year publication summary
|
132
|
170
|
309
|
383
|
330
|
372
|
390
|
372
|
370
|
303
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| F. Hoffmann-La Roche AG | 7932 |
71 |
| Takeda Pharmaceutical Company Limited | 2717 |
58 |
| H. Lundbeck A/S | 1241 |
47 |
| Hoffmann-La Roche Inc. | 3516 |
46 |
| The Regents of the University of California | 20230 |
36 |
| Janssen Pharmaceutica N.V. | 3349 |
36 |
| Sumitomo Pharma Co., Ltd. | 535 |
34 |
| Genentech, Inc. | 4008 |
29 |
| Taisho Pharmaceutical Co., Ltd. | 858 |
29 |
| Sumitomo Dainippon Pharma Co., Ltd. | 211 |
27 |
| Bristol-myers Squibb Company | 4848 |
26 |
| Pfizer Inc. | 3397 |
25 |
| Merck Sharp & Dohme LLC | 3734 |
25 |
| Novartis AG | 10656 |
24 |
| BIAL - Portela & CA, S.A. | 223 |
24 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 840 |
24 |
| The Johns Hopkins University | 5739 |
23 |
| Eisai R&D Management Co., Ltd. | 1210 |
23 |
| Osaka University | 3390 |
22 |
| AstraZeneca AB | 2857 |
21 |
| Other owners | 4800 |